GoAI
Get started
Option Care Health, Inc. logo

Option Care Health, Inc.

OPCH

NASDAQHealthcareMedical - Care Facilities

Open in GoAI

Previous close

$23.70

+$0.21 · +0.89%

Aug 21, 4:00 PM ET

OPCH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

72

Undervalued

Momentum

31

Weakening

Sentiment

76

Bullish

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Option Care Health, Inc. delivers infusion services to patients in their homes and other non-hospital settings throughout the United States. The company offers a broad spectrum of specialized infusion treatments, including therapies for various infections, management of heart failure, and comprehensive nutritional support (both intravenous and tube feeding) for individuals with acute or chronic conditions such as stroke, cancer, and digestive illnesses. They also provide immunoglobulin infusions for immune system deficiencies and treatments targeting chronic inflammatory disorders like Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Furthermore, Option Care Health assists in managing the progression of neurological conditions such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy. They also administer infusion therapies for bleeding disorders and provide crucial support for women experiencing high-risk pregnancies. Other specialized infusion services encompass pain relief, chemotherapy, and respiratory care. Complementing these medical offerings, the company provides professional nursing services. Option Care Health, Inc. maintains its primary corporate office in Bannockburn, Illinois.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
US
CEO
John C. Rademacher
Listed since
Aug 15, 1996
Employees
7,397

Market position

Day range

Current $23.70

52-week range

Current $23.70

Open
$23.49
Previous close
$23.49
Volume
1.6M
0.52× average
Average volume
3.06M
Average daily volume
Market cap
3.55B USD
Beta
0.61
Market reference 1
50-day average
$22.3162
+6.20% above average
200-day average
$27.3972
-13.49% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
6.21B USD
P/E (TTM)
17.82×
P/B (TTM)
2.91×
P/S (TTM)
0.62×
EV / EBITDA
14.89×
Earnings yield
4.02%
Free cash flow yield
4.20%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
18.17%
Operating margin
5.94%
Net margin
3.68%
Return on equity
15.65%
Return on assets
6.01%
Return on invested capital
9.33%

Financial health

Debt / equity
1.01×
Current ratio
1.53×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends25%17%9%2%Gross margin, FY2021: 22.67%Gross margin, FY2022: 21.98%Gross margin, FY2023: 22.81%Gross margin, FY2024: 20.27%Gross margin, FY2025: 18.06%Operating margin, FY2021: 5.55%Operating margin, FY2022: 6.09%Operating margin, FY2023: 7.31%Operating margin, FY2024: 6.44%Operating margin, FY2025: 5.98%Net margin, FY2021: 4.07%Net margin, FY2022: 3.82%Net margin, FY2023: 6.21%Net margin, FY2024: 4.24%Net margin, FY2025: 3.67%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 22.67%. Gross margin FY2022 21.98%. Gross margin FY2023 22.81%. Gross margin FY2024 20.27%. Gross margin FY2025 18.06%. Operating margin FY2021 5.55%. Operating margin FY2022 6.09%. Operating margin FY2023 7.31%. Operating margin FY2024 6.44%. Operating margin FY2025 5.98%. Net margin FY2021 4.07%. Net margin FY2022 3.82%. Net margin FY2023 6.21%. Net margin FY2024 4.24%. Net margin FY2025 3.67%.

Income trends

Revenue

5.65B USD+13.03%

Operating income

337.91M USD+4.99%

Net income

207.59M USD-2.00%
Income trends across reported periods6.2B USD4B USD1.79B USD−411.06M USDRevenue, FY2021: 3.44B USDRevenue, FY2022: 3.94B USDRevenue, FY2023: 4.3B USDRevenue, FY2024: 5B USDRevenue, FY2025: 5.65B USDOperating income, FY2021: 190.84M USDOperating income, FY2022: 240.23M USDOperating income, FY2023: 314.6M USDOperating income, FY2024: 321.83M USDOperating income, FY2025: 337.91M USDNet income, FY2021: 139.9M USDNet income, FY2022: 150.56M USDNet income, FY2023: 267.09M USDNet income, FY2024: 211.82M USDNet income, FY2025: 207.59M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 3.44B USD. Revenue FY2022 3.94B USD. Revenue FY2023 4.3B USD. Revenue FY2024 5B USD. Revenue FY2025 5.65B USD. Operating income FY2021 190.84M USD. Operating income FY2022 240.23M USD. Operating income FY2023 314.6M USD. Operating income FY2024 321.83M USD. Operating income FY2025 337.91M USD. Net income FY2021 139.9M USD. Net income FY2022 150.56M USD. Net income FY2023 267.09M USD. Net income FY2024 211.82M USD. Net income FY2025 207.59M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue5.65B USD5B USD4.3B USD3.94B USD3.44B USD
Cost of goods sold4.63B USD3.99B USD3.32B USD3.08B USD2.66B USD
Gross profit1.02B USD1.01B USD981.22M USD866.92M USD779.61M USD
Selling, general, and administrative682.45M USD630.25M USD607.43M USD566.12M USD525.71M USD
Operating expenses682.45M USD691.16M USD666.63M USD626.69M USD588.77M USD
Interest expense63.2M USD60.56M USD62.22M USD54.9M USD55.46M USD
Depreciation and amortization70.69M USD63.5M USD62.2M USD65.43M USD68.8M USD
Operating income337.91M USD321.83M USD314.6M USD240.23M USD190.84M USD
Net income207.59M USD211.82M USD267.09M USD150.56M USD139.9M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 0 misses, 2 met estimates
Average EPS surprise
+6.59%
11 comparable reports
Latest EPS result
0.45
Estimate 0.43 · Beat by 5.56%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.520.440.370.29Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MetQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 0.35, estimate 0.33, surprise +6.06%, Beat. Q2 2025, reported Apr 29, 2025: actual 0.4, estimate 0.36, surprise +11.11%, Beat. Q3 2025, reported Jul 30, 2025: actual 0.41, estimate 0.4, surprise +2.50%, Beat. Q4 2025, reported Oct 30, 2025: actual 0.45, estimate 0.43, surprise +4.65%, Beat. Q1 2026, reported Feb 24, 2026: actual 0.46, estimate 0.46, surprise 0.00%, Met estimate. Q2 2026, reported Apr 30, 2026: actual 0.4, estimate 0.37, surprise +8.11%, Beat. Q3 2026, reported Jul 29, 2026: actual 0.45, estimate 0.426, surprise +5.56%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 0.48, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.53B1.41B1.29B1.17BQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 1.35B USD, estimate 1.23B USD, surprise +9.49%, Beat. Q2 2025, reported Apr 29, 2025: actual 1.33B USD, estimate 1.34B USD, surprise -0.24%, Miss. Q3 2025, reported Jul 30, 2025: actual 1.42B USD, estimate 1.4B USD, surprise +0.96%, Beat. Q4 2025, reported Oct 30, 2025: actual 1.44B USD, estimate 1.46B USD, surprise -1.90%, Miss. Q1 2026, reported Feb 24, 2026: actual 1.47B USD, estimate 1.46B USD, surprise +0.25%, Beat. Q2 2026, reported Apr 30, 2026: actual 1.35B USD, estimate 1.39B USD, surprise -2.80%, Miss. Q3 2026, reported Jul 29, 2026: actual 1.44B USD, estimate 1.42B USD, surprise +1.60%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 1.47B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$28.43

19.96% upside
Past 12 months12-month forecastHigh $39.00Average $28.43Low $22.00

Rating distribution

15 ratings
Strong buy00%
Buy1173%
Hold427%
Sell00%
Strong sell00%

OPCH news

zacks.com

Are Investors Undervaluing Option Care Health (OPCH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and…

Read source
zacks.com

OPCH vs. PNTG: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Outpatient and Home Healthcare stocks have likely encountered both Option Care (OPCH) and The Pennant Group, Inc. (PNTG). But which of these two stocks offers value investors a…

Read source
zacks.com

Is Option Care Health (OPCH) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and…

Read source
defenseworld.net

Amundi Sells 38,525 Shares of Option Care Health, Inc. $OPCH

Amundi reduced its holdings in Option Care Health, Inc. (NASDAQ: OPCH) by 5.1% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional…

Read source
seekingalpha.com

Option Care Health, Inc. (OPCH) Q2 2026 Earnings Call Transcript

Option Care Health, Inc. (OPCH) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Option Care Health Q2 Earnings Call Highlights

Option Care Health NASDAQ: OPCH reported second-quarter 2026 results that exceeded its internal expectations, with revenue, adjusted EBITDA and adjusted earnings per share all improving sequentially. The home and…

Read source

Corporate actions

Corporate action history

Stock split

Effective Feb 3, 2020

1:4

OPCH peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding OPCH

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Mid-Cap ETF logoiShares Core S&P Mid-Cap ETFIJH
Market value
126.95M
Weight
0.10%
AUM
125.92B USD
Expense ratio
0.05%
Price / 1D
$76.77+0.52%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
115.1M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
95.24M
Weight
0.12%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
83.14M
Weight
0.04%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
48.19M
Weight
0.11%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
42.29M
Weight
0.65%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
41.66M
Weight
0.04%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
28.36M
Weight
0.19%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%

Continue in GoAI

Research OPCH

research.disclaimer